e-learning
resources
Virtual 2021
05.09.2021
COVID - 19 biomarkers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What is the best biomarker of COVID-19 pneumonia progression?
K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), B. Basina (Dnipro, Ukraine), N. Krabchenko (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine)
Source:
Virtual Congress 2021 – COVID - 19 biomarkers
Session:
COVID - 19 biomarkers
Session type:
E-poster
Number:
652
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), B. Basina (Dnipro, Ukraine), N. Krabchenko (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine). What is the best biomarker of COVID-19 pneumonia progression?. 652
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
The best coagulation marker for prediction of COVID-19 pneumonia progression.
Source: Virtual Congress 2021 – COVID - 19 biomarkers
Year: 2021
Determining the best diagnostic biomarker for sepsis and prognosis assessment
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
What new biomarkers are on the horizon for severe exacerbations?
Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC
Year: 2021
Low-t3 state a crucial biomarker in determining NIV failure and outcome in pulmonary patient?
Source: Annual Congress 2011 - Mechanical ventilation and weaning
Year: 2011
How exactly can we predict the prognosis of COPD?
Source: Eur Respir J 2006; 28: Suppl. 50, 807s
Year: 2006
How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …?
Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets?
Year: 2019
Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia?
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Biomarkers and VAP: results and perspectives
Source: Eur Respir Mon 2011; 53: 24-35
Year: 2011
Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?
Source: Eur Respir J 2016; 48: 279-281
Year: 2016
Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?
Source: Eur Respir J 2016; 48: 281-282
Year: 2016
Treatment of early lung disease – is it possible? Does it work?
Source: Annual Congress 2004 - PG19 - Screening for cystic fibrosis: diagnose early - treat early
Year: 2004
Monitoring of early lung disease: Is it clinically important to do routine infant lung function test?
Source: Annual Congress 2004 - PG19 - Screening for cystic fibrosis: diagnose early - treat early
Year: 2004
Biomarkers for fibrotic lung disease - new clinical benchmarks from the lab?
Source: Annual Congress 2013 –ME3 Biomarkers for fibrotic lung disease – new clinical benchmarks from the lab?
Year: 2013
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Year: 2019
How to manage a patient with COPD - early identification and how to prevent progression
Source: ERS Satellites 2021
Year: 2021
Are T2 biomarkers of any help in diagnosing asthma?
Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept